News

GT Apeiron Therapeutics, a novel biotechnology company, was launched with the backing from GT Healthcare and associated investors. The company also entered into a drug discovery…
Read More...

Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy in…
Read More...

Genmab A/S announced that it has entered into an exclusive worldwide license and option agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize HexaBody-CD38, a…
Read More...

Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, and Zai Lab Ltd., a China and U.S.-based innovative…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Polivy (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan…
Read More...

Hoth Therapeutics, a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as…
Read More...

Merck, known as MSD outside the United States and Canada, announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical…
Read More...

CStone Pharmaceuticals announced that the company has entered into a global clinical collaboration with China focus with Bayer HealthCare LLC to evaluate the safety, tolerability,…
Read More...

Biogen announced that it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for…
Read More...

Bayer and Arvinas, a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins, announced an agreement to leverage Arvinas’ novel PROTAC protein…
Read More...

Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an…
Read More...

Vertex Pharmaceuticals Incorporated announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic…
Read More...

Novartis announced new early stage histology data in kidney transplantation, suggesting that with investigational compound iscalimab (CFZ533) it may be possible to prolong the…
Read More...

Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases, announced it has initiated dosing in a Phase 1 clinical trial…
Read More...

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, has signed an agreement with BDD Pharma, an award-winning drug delivery company specializing in modified and…
Read More...

Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, announce that they have signed a manufacturing…
Read More...

Advanced Accelerator Applications S.A. (AAA), a Novartis company, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted…
Read More...

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company announced a strategic partnership with Seattle-based PharmaIN Corporation for the purpose of investigating the use of…
Read More...

CStone Pharmaceuticals announced that it has received approval to initiate clinical development in China of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced…
Read More...